Alpha Tau Medical Ltd.
DRTSNASDAQHealthcare● Active
$9.28
$-0.07(-0.75%)
Market Cap$838224129
P/E Ratio—
52W High$11.62
52W Low$2.81
Alpha Tau Medical Ltd. (DRTS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DRTS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 18, 2026EPS Actual
-$0.26
Est. -$0.13 · -100.0%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 18, 2026
After Market Close
▼ Miss EPS
DRTS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.14 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 18, 2026 | -$0.13 | -$0.26 | -100.0% | — | $0.00B | — |
| ▼ Q1 FY2026 | Mar 9, 2026 | -$0.13 | -$0.14 | -7.7% | — | $0.00B | — |
| ▼ Q4 FY2025 | Nov 20, 2025 | -$0.12 | -$0.14 | -16.7% | — | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.12 | -$0.13 | -8.3% | — | — | — |
| ▲ Q2 FY2025 | May 19, 2025 | -$0.14 | -$0.12 | +14.3% | — | $0.00B | — |
| — Q1 FY2025 | Mar 12, 2025 | -$0.13 | -$0.13 | +0.0% | — | — | — |
| ◌ Q4 FY2024 | Nov 21, 2024 | -$0.13 | — | — | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.14
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 18, 2026Miss
EPS Actual
-$0.26
EPS Est.
-$0.13
EPS Surpr.
-100.0%
Revenue
—
Q1 FY2026
Mar 9, 2026Miss
EPS Actual
-$0.14
EPS Est.
-$0.13
EPS Surpr.
-7.7%
Revenue
—
Q4 FY2025
Nov 20, 2025Miss
EPS Actual
-$0.14
EPS Est.
-$0.12
EPS Surpr.
-16.7%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.13
EPS Est.
-$0.12
EPS Surpr.
-8.3%
Revenue
—
Q2 FY2025
May 19, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.14
EPS Surpr.
+14.3%
Revenue
—
Q1 FY2025
Mar 12, 2025
EPS Actual
-$0.13
EPS Est.
-$0.13
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2024
Nov 21, 2024
EPS Actual
—
EPS Est.
-$0.13
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $0.33 | $0.33 | $0.33 | 1 |
| Q3 FY2030 | $0.24 | $0.24 | $0.24 | 1 |
| Q2 FY2030 | $0.15 | $0.15 | $0.15 | 1 |
| Q1 FY2030 | $0.16 | $0.16 | $0.16 | 1 |
| Q4 FY2029 | $0.16 | $0.16 | $0.16 | 1 |
| Q3 FY2029 | $0.09 | $0.09 | $0.09 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2030 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2030 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2030 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2029 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 18, 2026 | -100.0% | $10.36 | $10.03 | -3.19% |
| ▼ Q1 FY2026 | Mar 9, 2026 | -7.7% | $6.41 | $6.71 | +4.68% |
| ▼ Q4 FY2025 | Nov 20, 2025 | -16.7% | $3.68 | $3.47 | -5.71% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -8.3% | $3.39 | $3.56 | +5.01% |
| ▲ Q2 FY2025 | May 19, 2025 | +14.3% | $2.79 | $3.10 | +11.11% |
| ▲ Q1 FY2025 | Mar 12, 2025 | +0.0% | $2.60 | $2.66 | +2.31% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +15.4% | $2.10 | $2.11 | +0.48% |
| ▲ Q2 FY2024 | May 20, 2024 | +15.4% | $2.83 | $2.71 | -4.24% |
Q2 FY2026-3.19%
Report Date
May 18, 2026
EPS Beat/Miss
-100.0%
Price Before
$10.36
Price After
$10.03
Q1 FY2026+4.68%
Report Date
Mar 9, 2026
EPS Beat/Miss
-7.7%
Price Before
$6.41
Price After
$6.71
Q4 FY2025-5.71%
Report Date
Nov 20, 2025
EPS Beat/Miss
-16.7%
Price Before
$3.68
Price After
$3.47
Q3 FY2025+5.01%
Report Date
Aug 11, 2025
EPS Beat/Miss
-8.3%
Price Before
$3.39
Price After
$3.56
Q2 FY2025+11.11%
Report Date
May 19, 2025
EPS Beat/Miss
+14.3%
Price Before
$2.79
Price After
$3.10
Q1 FY2025+2.31%
Report Date
Mar 12, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.60
Price After
$2.66
Q3 FY2024+0.48%
Report Date
Aug 14, 2024
EPS Beat/Miss
+15.4%
Price Before
$2.10
Price After
$2.11
Q2 FY2024-4.24%
Report Date
May 20, 2024
EPS Beat/Miss
+15.4%
Price Before
$2.83
Price After
$2.71
Avg Beat Reaction+2.42%
Avg Miss Reaction+0.20%
Beat Rate4 / 8 quarters
Largest Move+11.11% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DRTS ends December
Alpha Tau Medical Ltd. (DRTS) most recently reported earnings on May 18, 2026 for Q2 FY2026, posting EPS of $-0.26 — missing the analyst consensus of $-0.13 by -100.0%. The next DRTS earnings date is expected around September 1, 2026.
Each quarter, investors track DRTS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DRTS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DRTS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DRTS earnings · 5 questionsAlpha Tau Medical Ltd.'s next earnings report is expected around September 1, 2026. DRTS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DRTS historically reports after market close (AMC).
DRTS earnings datewhen is DRTS earningsDRTS next earnings datewhen does DRTS report earningsDRTS earnings calendar
▸ Source: FMP · Alpha Tau Medical Ltd. SEC filings · US GAAP · Alpha Tau Medical Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026